Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

bioMérieux’s New Formulation VITEK® 2 Fungal Susceptibility Card

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
Offers automated, standardized and rapid yeast susceptibility testing.

bioMérieux has created a new Fungal Susceptibility Card for susceptibility testing of Candida species and Cryptococcus neoformans.

The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.

Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations.

Early diagnosis and prompt treatment are the key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardized and rapid yeast susceptibility testing.

The VITEK 2 AST-YS07 Fungal Susceptibility Card, which replaces VITEK 2 AST-YS06, complements the current antifungals - amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole - with micafungin, an echinocandin active against Candida species, further extending the capabilities of the VITEK 2 and helping to ensure that the correct treatment is swiftly initiated.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

bioMérieux Makes a Significant Acquisition in Molecular Biology in the U.S.
With the acquisition of BioFire, bioMérieux consolidates its position as a major player in infectious disease diagnostics.
Thursday, September 05, 2013
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!